Take­da takes $140M hit on Phase 3 epilep­sy flop, pre­views late-stage tri­als for pipeline prospects

Take­da is reg­is­ter­ing a JPY $21.5 bil­lion ($140 mil­lion) im­pair­ment on its Ovid-li­censed epilep­sy drug in light of neg­a­tive Phase 3 re­sults, the Japan­ese drug­mak­er …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER